Page last updated: 2024-09-03

pak 104p and EHS Tumor

pak 104p has been researched along with EHS Tumor in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cao, S; Minderman, H; Rustum, YM; Scheper, RJ; Slovak, ML; Tóth, K; Vanhoefer, U	1

Other Studies

1 other study(ies) available for pak 104p and EHS Tumor

Article	Year
PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:2 Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Cyclic P-Oxides; Doxorubicin; Drug Resistance, Neoplasm; Glutathione; Humans; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Transplantation; Nicotinic Acids; Paclitaxel; Sarcoma, Experimental; Transplantation, Heterologous; Tumor Cells, Cultured	1996

Article

Year

PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein.

Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:2

Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Cyclic P-Oxides; Doxorubicin; Drug Resistance, Neoplasm; Glutathione; Humans; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Transplantation; Nicotinic Acids; Paclitaxel; Sarcoma, Experimental; Transplantation, Heterologous; Tumor Cells, Cultured

1996